Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
12278A Clinical Urology Research Screening Protocol
15550B Bladder Cancer Sample Collection
Select
09-288-B Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
Select
11-0646 S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
Select
IRB13-0416 An Integrated Phase II/III, Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma In Situ Disease (NMIBCis, meaning cis and cis with TA and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy.
Select
IRB13-1410 A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT) and Received Prior Treatment with Induction Bacille Calmette-Guerin (BCG)
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0105 A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3
Select
IRB14-1040 Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
CIRB14-1105 S1314: A Randomized Phase II Study of Co-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Select
IRB14-1229 A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
Select
IRB14-1429 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumor
Select
IRB15-0330 A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in combination with Bevacizumab Versus Sunitinib in Untreated Advanced Renal Cell Carcinoma
CIRB14-1513 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladde
IRB15-0310 Randomized Phase II Trial of ACP-196 and Pembrolizumab Immunotherapy Dual Check Point Inhibitation in Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK study)
IRB15-0266 An Open Label, Single Arm, Phase II, Multicenter Study of The Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With No-Muscle Invasive Bladder Carcinoma Who Have Failed BCG Therapy and Refused Cystectomy
Select
IRB15-0322 An Open-Label, Single-Arm, Phase 2 Study of Moncetinostat in Selected Patients with Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team